Distinctive pseudopalisaded histiocytic hyperplasia characterizes the transition of exudative to proliferative phase of diffuse alveolar damage in patients dying of COVID-19

[1]  D. Annane,et al.  Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis , 2021, Intensive Care Medicine.

[2]  C. Conrad,et al.  Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19 , 2020, Nature Biotechnology.

[3]  D. Wichmann.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[4]  Taher Entezari-Maleki,et al.  A comprehensive review on sarilumab in COVID-19 , 2020, Expert opinion on biological therapy.

[5]  André F. Rendeiro,et al.  The spatio-temporal landscape of lung pathology in SARS-CoV-2 infection , 2020, medRxiv.

[6]  K. Mertz,et al.  Two distinct immunopathological profiles in autopsy lungs of COVID-19 , 2020, Nature Communications.

[7]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[8]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[9]  A. Borczuk,et al.  COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City , 2020, Modern Pathology.

[10]  J. Weitz,et al.  COVID-19 coagulopathy, thrombosis, and bleeding , 2020, Blood.

[11]  E. Burks,et al.  SARS-CoV-2 Infection–Associated Hemophagocytic Lymphohistiocytosis , 2020, American journal of clinical pathology.

[12]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[13]  J. van Paassen,et al.  A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression , 2020, Modern Pathology.

[14]  I. Solomon,et al.  In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19 , 2020, Modern Pathology.

[15]  J. Myers,et al.  Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD , 2020, Histopathology.

[16]  Andrea Gianatti,et al.  Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.

[17]  M. Aepfelbacher,et al.  Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany , 2020, International Journal of Legal Medicine.

[18]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[19]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[20]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[21]  Anne Kimball,et al.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.

[22]  Nan Tang,et al.  SARS-CoV-2 and viral sepsis: observations and hypotheses , 2020, The Lancet.

[23]  Subha Ghosh,et al.  COVID-19 Autopsies, Oklahoma, USA , 2020, American journal of clinical pathology.

[24]  S. Xiao,et al.  Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies , 2020, Modern Pathology.

[25]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[26]  Haibo Xu,et al.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer , 2020, Journal of Thoracic Oncology.

[27]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[28]  W. Lim,et al.  Corticosteroids as adjunctive therapy in the treatment of influenza. , 2019, The Cochrane database of systematic reviews.

[29]  G. Van den Berghe,et al.  Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017 , 2018, Intensive Care Medicine.

[30]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[31]  J. Scheller,et al.  IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling , 2013, The Journal of Immunology.

[32]  E. V. van Gorp,et al.  Review: Viral infections and mechanisms of thrombosis and bleeding† , 2012, Journal of medical virology.

[33]  R. Hyzy,et al.  Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. , 2006, The New England journal of medicine.

[34]  J. Tomashefski.  Pulmonary pathology of acute respiratory distress syndrome. , 2000, Clinics in chest medicine.

[35]  J. Tomashefski,et al.  Regional alveolar damage (RAD). A localized counterpart of diffuse alveolar damage. , 1989, American journal of clinical pathology.

[36]  A. Katzenstein.  Pathogenesis of "fibrosis" in interstitial pneumonia: an electron microscopic study. , 1985, Human pathology.